The European Commission (EC) has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC).  Rretifanlimab is the first systemic treatment for adult patients with advanced SCAC in Europe.  The EC approval is based […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!